EMAIL THIS PAGE TO A FRIEND

Pharmacopsychiatry

Effect of Adjunctive Celecoxib on BDNF in Manic Patients Undergoing Electroconvulsive Therapy: a Randomized Double Blind Controlled Trial.


PMID 26398281

Abstract

The possible effect of inflammatory factors on decreasing BDNF has been proposed in the literature. There is conflicting evidence regarding association between BDNF level alteration and treatment response in depressive patients undergoing electroconvulsive therapy (ECT). This study investigated the effects of celecoxib in manic patients undergoing ECT on treatment response and BDNF levels. This randomized, double-blind, clinical trial included 35 manic patients who received either celecoxib (200 mg twice daily) or placebo, from one day before the 1(st) ECT session throughout the 6(th) session. BDNF levels were measured at baseline, 1(st), 3(rd) and 6(th) ECT sessions. Young mania rating scale was used to assess treatment response. Adding celecoxib was not associated with a significant rise in BDNF levels following ECT. No difference was noted between groups in terms of treatment response. No significant association was found between changes in BDNF levels and patients' responses. Adjuvant celecoxib did not significantly affect the BDNF level or the treatment response following ECT in manic patients.